Study Gives Hope of Altering Genes to Repel H.I.V.
By Denise Grady,
The New York Times
| 03. 05. 2014
The idea of genetically altering people’s cells to make them resist the virus that causes AIDS may seem like a pipe dream, but a new report suggests it can be done.
The research involves the first use in humans of “gene editing,” a treatment that zeros in on a particular gene and disables it.
In 12 people infected with H.I.V., scientists used the technique to get rid of a protein on the patients’ immune cells that the virus must latch onto to invade the cells. Cells were removed from the patients, treated and then dripped back into their bloodstreams through an intravenous line.
In theory, if enough cells could be engineered to repel the virus, patients might no longer need antiviral drugs, and might in effect be cured.
The experiment was a pilot study, meant to test safety, not efficacy. It found that immune cells could be altered, and that doing so did not harm patients. The gene editing also seemed to help fight the infection in some cases, but the findings are preliminary and researchers cautioned that widespread use...
Related Articles
By Matthew Herper, Stat | 07.01.2026
Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It’s a piece of science that generates as many questions as answers. They...
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Emily Baumgaetner Nunn, The New York Times | 07.20.2026
The National Institutes of Health recently announced a remarkable achievement: the world’s largest database of human genomes, a repository of information that the agency says will help usher in a new era in personalized medicine.
Scientists are already developing clinical...
By Risa Cromer, The Conversation | 07.17.2026